Most Active UK Investors (April 2026 Edition): Angels and VCs
A monthly ranking based on Startupmag's tracking of active UK angel and venture capital investment.
March 2026’s most active investors ranking reflects where UK capital was actually deployed in March 2026, spanning pre-seed, seed and growth rounds across angels, venture capital firms and corporate investors.
The analysis is based on Startupmag’s investor database, tracking live investment activity across thousands of UK angel investors, venture capital firms and corporate investment arms.
Across angels, venture capital and corporate backers the month showed a clearly layered capital stack. Angels concentrated on pre-seed and seed tickets validating product and go-to-market hypotheses. Venture funds formed the middle layers, scaling validated startups into larger institutional rounds. Corporate and bank-linked investors supplied the largest cheques, particularly in health, sustainability and industrial AI where strategic adjacency and R&D alignment matter most.
The pipeline was dominated by AI-inflected B2B SaaS, healthtech and biotech, alongside energy and climate-linked industrial technologies. Fintech and proptech maintained steady activity, while HRtech and ecommerce attracted operator angels bringing commercial expertise.
- Angels clustered at pre-seed and seed, typically in the £200k to £4m band, providing early validation, operator credibility and signalling power.
- VC firms formed the scaling ladder, deploying capital from structured seed rounds through £3m to £15m scale allocations and into £20m+ growth rounds.
- Corporate and bank-linked investors focused on strategic sectors such as biotech, energy and sustainability, supplying large capital alongside commercial pathways.
These dynamics point to a steady but increasingly specialised market. Early experimentation remains strong, particularly around AI applications, but capital is concentrating into companies demonstrating clear commercial pathways, technical defensibility and global scalability.
Angel investors: early signal across £200k–$4,000,000 pre-seed and seed rounds
Konstantin Vinogradov, Steven Bartlett, Hugo Rodger Brown, Tom Gozney, Andy Gray and Gareth Williams emerged as the most visible individual angels in March 2026, each linked to a headline deal. Their activity clustered around AI and HRtech, with a parallel stream of ecommerce and consumer product bets, notably design-led physical goods and retail tech. Several are operator angels or public-facing figures whose names carry weight, including Steven Bartlett and ex-Skyscanner founder Gareth Williams.
Patterns of participation were distinct and predictable. Konstantin Vinogradov fronted larger, thematic AI pre-seed rounds, exemplified by xmemory’s $4,000,000 pre-seed. Steven Bartlett was visible in HRtech and AI seed plays such as Ivee at $1,000,000. Hugo Rodger Brown and Tom Gozney showed an operator-investor profile, backing sector-aligned pre-seed opportunities like First Concepts at £750,000 and Allday Goods at £765,000 respectively. Andy Gray focused on ecommerce tech with Voxelo at £650,000, while Gareth Williams represented more locally scaled early pre-seed involvement with SWURF at £200,000. All amounts reported are the sizes of the funding rounds rather than the individual angel cheques.
Comparatively, public-facing angels such as Bartlett tend to join visible seed rounds that attract follow-on interest. Operator angels like Gozney and Rodger Brown provide hands-on commercial validation and often populate the £650k–£800k pre-seed band. Thematic AI investors appear in multi-million-dollar pre-seed tickets that anticipate rapid enterprise uptake. Their participation complements institutional seed and VC capital by de-risking product and go-to-market hypotheses and signalling readiness for scaling. For founders the message is clear: AI and HRtech are where momentum and smart capital are concentrating this month, while consumer and ecommerce teams will find the deepest traction by courting experienced operator angels who can unlock category-specific growth.
Venture capital firms: £200k–$105m from pre-seed to growth rounds across AI, healthtech and deep tech
| Venture Capital Firms | March Investments | Investment Sector | Location | Funding Round | Contact Details |
|---|---|---|---|---|---|
 Fuel Ventures(more info 🔒) Fuel Ventures is a venture capital firm that focuses on backing ambitious t... | Deaku (£480,000, Media) Flexzo AI (£9,000,000, Healthtech) Numonic (£250,000, AI) JAAQ ($17,000,000, Healthtech) instep.ai (£900,000, Proptech) |  London | |||
 SFC Capital(more info 🔒) SFC Capital is a venture capital firm that focuses on investing in early-st... | Plato (£260,000, Edtech) Hydra Manufacturing (£320,000, Material) Regeno (£420,000, Energy) Rivulo (£375,000, AI) | London | |||
Vuelo (£56,000,000, Fintech) Keith (£2,000,000, Legaltech) | London | ||||
Payr ($2,100,000, Fintech) VerbaFlo ($7,000,000, AI) | Stamford | ||||
Isembard (£37,000,000, Hardware) Tropic ($105,000,000, Agtech) | London, Cambridge |
Fuel Ventures and SFC Capital were the busiest VCs in March, with notable activity also from Haatch, IQ Capital and BackedVC. The month was dominated by AI-inflected rounds across healthtech, proptech, fintech and B2B SaaS, with pockets of greentech, deep-tech hardware and agtech. Specialist models were visible too: university spinouts, regional partners and co-investment platforms played clear roles in several rounds, including participation by the British Business Bank. Taken together, these flows point to a UK market that remains feedstock-rich at seed and pre-seed while channelling innovations into sector-specific scale-ups. Corporate and strategic investors appear focused on industry adjacency, R&D alignment, regulatory or clinical pathways and infra-scale commitments.
Each firm showed a distinct pattern. Fuel Ventures scans the spectrum, backing pre-seed and seed deals in the £200k–£800k band, including Numonic £250k and Deaku £480k. It also participates in intermediate rounds such as instep.ai at c.£0.9m and steps into Series A and growth financings in the £3m–£15m band, exemplified by Flexzo AI £9m and JAAQ $17m. SFC Capital is tightly focused on pre-seed technology and greentech within the £200k–£800k band, with deals including Plato £260k, Hydra Manufacturing £320k, Regeno £420k and Rivulo £375k. By contrast BackedVC and IQ Capital sit at the higher end: BackedVC paired a seed-stage legaltech investment, Keith £2m, with a headline growth round for Vuelo £56m, while IQ Capital is driving deep-tech scale with growth rounds well into the £20m+ band such as Isembard £37m and Tropic $105m. Haatch occupies the middle ground, targeting B2B SaaS and proptech with tickets from roughly £0.5m–£2m, for example Payr c.£1.56m, up to the £3m–£15m band with VerbaFlo c.£5.3m.
The pattern reveals complementary roles across the ecosystem. Early-stage investors such as SFC and parts of Fuel and Haatch seed technical experimentation and product-market fit. Mid-stage players consolidate traction, and growth-focused funds like IQ Capital and BackedVC supply the large cheques needed for industrial and international expansion. Regional and mission-led funds, university-backed spinouts and co-investment vehicles are de-risking capital and widening geographical and sectoral pipelines, especially in energy, advanced manufacturing and agtech. Venture studios and repeatable operator networks turn nascent ideas into investible startups. In short, early innovation is feeding mid-market commercialisation and attracting large-scale growth capital, creating a layered ecosystem that supports companies from lab to large-scale markets.
Corporate venture capital: strategic cheques in biotech, energy and sustainability
| Corporate Venture Capital Firms | March Investments | Investment Sector | Location | Funding Round | Contact Details |
|---|---|---|---|---|---|
Bioliberty ($10,200,000, Healthtech) | Edinburgh | ||||
Tropic ($105,000,000, Agtech) | Amsterdam, Netherlands | ||||
Oxa (£77,000,000, Mobility) | |||||
Mestag Therapeutics ($40,000,000, Biotech) | NY, US | ||||
Nscale (£1,500,000,000, AI) |
March 2026’s corporate dealflow was led by a mix of energy and industrial CVCs, life science strategics and bank-backed funds. bp Ventures, Johnson & Johnson’s JJDC, ABN AMRO’s Sustainable Impact Fund and the Scottish National Investment Bank were particularly active. Activity clustered into two clear groups: biotech and healthtech on one side, and energy, mobility plus climate and agri-tech on the other. Sustainability-focused growth rounds attracted notable attention. Bank-linked players played a prominent role alongside traditional corporates, while insurer-linked units and venture studios were less visible this month. The pattern underlines a corporate emphasis on R&D protection, strategic adjacency and practical scale-up support rather than purely financial returns.
Each investor demonstrated a distinct strategic footprint. JJDC reinforced its appetite for science-led clinical progression by backing Cambridge-based Mestag Therapeutics in the upper clinical range with a roughly £30.1m ($40m) growth round to fund a Phase I programme and platform expansion. bp Ventures sat in the large strategic tier with Oxa’s £77m Series D first close, prioritising industrial AI and autonomous mobility deployments across ports and energy sites. ABN AMRO’s SIF occupied the large-scale sustainability bracket with Tropic’s $105m Series C to industrialise gene-edited crops. The Scottish National Investment Bank played a support and commercialisation role by helping Bioliberty raise about $10.2m to accelerate US rollout and product enhancements.
Viewed comparatively, pharma CVCs like JJDC remain the go-to backers for de-risking mid-stage clinical programmes and preserving future R&D optionality. Industrial corporates such as bp favour capital in the large, deployment-oriented tier to secure operational adjacencies and infrastructure scale. Banks and bank-affiliated funds supply structured, patient growth capital and sustainability credentials that bridge venture and commercial markets. Insurer-linked units, when active, typically target strategic fintech and risk-transfer plays, and venture studios concentrate on early, build-stage bets that seed future portfolios. The interaction of early scientific bets, mid-stage clinical funding, corporate-led industrial adoption and bank-structured growth finance is creating layered pathways from lab to market and shaping corporate-backed innovation across the UK and Europe.
Across the market a clear throughline emerged: AI-enabled tooling, health and sustainability dominated dealflow while consumer and ecommerce bets continued to attract hands-on operator investors. Angels supplied early-stage validation and category expertise that de-risked seed hypotheses. VCs then layered capital from seed through growth to consolidate product-market fit and commercial scale. Corporate and bank-linked investors provided larger strategic cheques and operational pathways for mid-to-late deployment.
Tactically, angels skewed to pre-seed and seed bands with practical commercial support. Institutional VCs occupied the middle ground with specialist and regional programmes feeding larger growth financings. Corporates prioritised R&D adjacency and infrastructure-scale commitments. For founders the practical takeaway is clear: secure operator or thematic angel backing to demonstrate traction, align with VCs whose stage and sector focus match your scaling plan, and treat corporate capital as a strategic lever when regulatory, clinical or deployment pathways make it the most value-accretive option.
Click here for a full list of 7,526+ startup investors in the UK